Sulbactam, durlobactam (Xacduro) - To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Skip to main contentSkip to FDA SearchSkip to footer links An official website of the United States government Here's how you know U.S. Food and Drug Administration Search MenuSearch FDASubmit search Home Drugs Drug Approvals and Databases Drugs@FDADrug Approval
Cefepime-enmetazobactam for treating hospital-acquired pneumonia including ventilator-associated pneumonia Cefepime-enmetazobactam for treating hospital-acquired pneumonia including ventilator-associated pneumonia - NIHR Innovation Observatory * Who we are * What we do * Our Networks * Engage * Events * News * Resources Get in touch * * A world leading Horizon Scanning Facility The NIHR pneumonia including ventilator-associated pneumoniaCefepime-enmetazobactam is in clinical development for the treatment of adults with hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP). Pneumonia is a type of chest infection where tiny air sacs in lungs (alveoli) fill with fluid, making it harder to breathe. Cefepime-enmetazobactam is in clinical development
Pneumocystis jirovecii pneumonia Skip to main contentSkip to searchEnglish (US)EnglishPortuguês中文Log in#{autosuggest.search}#{autosuggest.search}HomePneumocystis jirovecii pneumonia MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:7 Jan 2024Last updated:02 Feb 2024SummaryThe organism Pneumocystis jirovecii was known formerly as Pneumocystis carinii.Suspicion for Pneumocystis pneumonia (PCP) is based on clinical signs or symptoms of pneumonia in a person with immune suppression, especially when due to HIV infection.Diagnosis is made by detection of the organism in either induced sputum or bronchoalveolar lavage.The treatment of choice is trimethoprim/sulfamethoxazole.The incidence of PCP is declining with the use of combination antiretroviral therapy and PCP
Organising pneumonia Skip to main contentSkip to searchEnglish (US)EnglishPortuguês中文Log inSearchSearchHomeOrganising pneumonia MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:28 May 2024Last updated:25 Jun 2024Summary Organising pneumonia (OP) is an inflammatory disorder involving both the peripheral bronchioles and alveoli simultaneously. It has distinctive radiographic findings, histological features, and response to corticosteroids (unlike usual interstitial pneumonia). OP may be caused by multiple insults such as medication, infection, rheumatological disease, autoimmune disease, post-transplantation, radiation, and environmental causes. In cryptogenic organising pneumonia, a cause cannot be elicited after a careful history, examination and pertinent
Atypical pneumonia Atypical pneumonia - Symptoms, diagnosis and treatment | BMJ Best PracticeSkip to main contentSkip to search * English (US)EnglishPortuguês中文 * Log in * Personal account * Access through your institution(Open Athens) * Subscribe * Access through your institution * Log in * English (US)EnglishPortuguês中文 HomeSearchSearchHome * About usOverviewWhat is BMJ Best Practice?Our * Investigations * Differentials * Management * Approach * Treatment algorithm * Emerging * Prevention * Patient discussions * Follow up * Complications * Prognosis * Resources * Guidelines * Images and videos * References * Patient information * Calculators * Evidence * Ver contenido en español This topic is available for freeLast reviewed: 16 Aug 2024Last updated: 10 Sep 2024SummaryAtypical pneumonia
Community-acquired pneumonia in children Community-acquired pneumonia in children - Symptoms, diagnosis and treatment | BMJ Best PracticeSkip to main contentSkip to search * English (US)EnglishPortuguês中文 * Log in * Personal account * Access through your institution(Open Athens) * Subscribe * Access through your institution * Log in * English (US)EnglishPortuguês中文 HomeSearchSearchHome * About viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance. OKCancelCommunity-acquired pneumonia in children Menu Close * Overview * Theory * Diagnosis * Management * Follow up * Resources * Overview * Summary * Theory * Epidemiology * Aetiology * Case history
Overview of pneumonia Overview of pneumonia - Summary of relevant conditions | BMJ Best PracticeSkip to main contentSkip to search * English (US)EnglishPortuguês中文 * Log in * Personal account * Access through your institution(Open Athens) * Subscribe * Access through your institution * Log in * English (US)EnglishPortuguês中文 HomeSearchSearchHome * About usOverviewWhat is BMJ Best Practice?Our impactCustomer stories * Browse clinical contentRecent updatesSpecialtiesTry a free topicPatient informationVideosCalculators * What’s newClinical updatesNewsPodcast * AccessLog in via...Personal subscription or user profileAccess through your institutionAccess codeSubscribeFree trialHow do I get access?Download the app * HelpFAQsHow do I get access?Contact us Overview of pneumonia Menu Close * Overview
Aztreonam / avibactam (Emblaveo) - for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia and infections due to aerobic Gram-negative organisms This site uses cookies. Visit our cookies policy page or click the link in any footer for more information and to change your preferences.Accept all cookiesAccept only essential cookiesSkip to main of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia and infections due to aerobic Gram-negative organisms in patients with limited treatment options. The applicant for this medicinal product is Pfizer Europe MA EEIG.Emblaveo was reviewed under EMA’s accelerated assessment programme.Emblaveo is a fixed dose combination of two active substances (ATC code: J01DF51 aztreonam
Ceftobiprole medocaril sodium (Zevtera) - To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia Drug Approval Package: ZEVTERA * Skip to main content * Skip to FDA Search * Skip to footer links An official website of the United States governmentHere's how you know The .gov means it's official.Federal government
Hospital-acquired pneumonia (non COVID-19) Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageHospital-acquired pneumonia (non COVID-19) MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:17 Apr 2023Last updated:16 May 2023SummaryHospital-acquired pneumonia (HAP) is typically caused by bacteria, especially aerobic gram-negative bacilli, such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Acinetobacter species.Patients usually present with a combination of fever (or hypothermia), leukocytosis (or leukopenia), purulent sputum, and poor oxygenation. A new and/or persistent alveolar shadowing on chest x-ray or computed tomography scan confirms the diagnosis.Obtain
Community-acquired pneumonia (non COVID-19) Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageCommunity-acquired pneumonia (non COVID-19) MENUThis topic is available for freeLast reviewed:10 Jan 2023Last updated:31 Jan 2023SummaryCommunity-acquired pneumonia (CAP) typically presents with symptoms and signs % (or <88% in patients at risk of CO2 retention).Consider sepsis whenever an acutely unwell person presents with likely infection, even if their temperature is normal. Follow your local protocol for prompt management of all patients with suspected sepsis, or those at risk.DefinitionCommunity-acquired pneumonia (CAP) is defined as pneumonia acquired outside hospital or healthcare facilities. Clinical
Aspiration pneumonia Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageAspiration pneumonia MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:30 Jul 2023Last updated:24 Aug 2023SummaryAspiration pneumonia is diagnosed based on clinical signs or symptoms of pneumonia in a person with a history of, or risk factors for, aspiration.Chest x-ray will show a new infiltrate; infection usually involves the dependent lung lobe. Sputum culture and Gram stain are usually inconclusive but may identify the infecting organism.Complications of disease include lung abscess and empyema.Aspiration pneumonia predominantly occurs in older adults. As such, the recommendations in this topic are principally
Guideline on management of pneumonia and diarrhoea in children up to 10 years of age Guideline on management of pneumonia and diarrhoea in children up to 10 years of age Guideline on management of pneumonia and diarrhoea in children up to 10 years of age Guideline on management of pneumonia and diarrhoea in children up to 10 years of ageISBN 978-92-4-010341-2 (electronic version)ISBN 978-92-4 by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization ( citation. Guideline on management of pneumonia
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia Antimicrobial prescribing: delafloxacin for community-acquired pneumonia Evidence summary Published: 10 August 2021 www.nice.org.uk/guidance/es37 pathwaysProduct overview Product overview The content of this evidence summary was up to date in August 2021. See summaries of product characteristics (SPCs), British National Formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information. Delafloxacin (Quofenix, Menarini) is a fluoroquinolone antibiotic, which is available as a powder for infusion and a tablet. It has a marketing authorisation for community-acquired pneumonia in adults when it is considered inappropriate to use other antibacterial agents
Chest physiotherapy for pneumonia in adults. Despite conflicting evidence, chest physiotherapy has been widely used as an adjunctive treatment for adults with pneumonia. This is an update of a review first published in 2010 and updated in 2013. To assess the effectiveness and safety of chest physiotherapy for pneumonia in adults. We updated our searches in the following databases to May 2022 : the Cochrane Central Register of Controlled Trials (CENTRAL) via OvidSP, MEDLINE via OvidSP (from 1966), Embase via embase.com (from 1974), Physiotherapy Evidence Database (PEDro) (from 1929), CINAHL via EBSCO (from 2009), and the Chinese Biomedical Literature Database (CBM) (from 1978). Randomised controlled trials (RCTs) and quasi-RCTs assessing the efficacy of chest physiotherapy for treating pneumonia
Mepolizumab (Nucala) - for the treatment of chronic eosinophilic pneumonia Prepared by the All Wales Therapeutics and Toxicology Centre Page 1 of 4 Mepolizumab (Nucala®▼) for the treatment of chronic eosinophilic pneumonia (OW15) May 2022 ONE WALES INTERIM DECISION Mepolizumab (Nucala®▼) for the treatment of chronic eosinophilic pneumonia Date of original advice: November 2019 Date of review: May 2022 The following One Wales Medicines Assessment Group (OWMAG) recommendation has been endorsed by health board Chief Executives. It is the view of the One Wales Medicines Advisory Group (OWMAG) that mepolizumab (Nucala®) should continue to not be supported within NHS Wales for the treatment of chronic eosinophilic pneumonia. Individual Patient Funding Request (IPFR) consideration
Clinical outcomes for community-acquired pneumonia PSI vs the CURB-65. Clinical outcomes for community-acquired pneumonia PSI vs the CURB-65. – Less Is MoreSkip to content * Home * About * Index * FeedbackSearch for:Less Is MoreSimpler & Better MedicineMenuClinical outcomes for community-acquired pneumonia PSI vs the CURB-65. — February 7, 2024Clinical outcomes for community-acquired pneumonia PSI vs the CURB-65.February 7, 2024January 29, 2024/bcayleySummary: For patients with possible community-acquired pneumonia (CAP), risk-stratification with the CURB-65 score may be associated with lower 30-day mortality compared to risk stratification with the (longer) Pneumonia Severity Index (PSI).https://pubmed.ncbi.nlm.nih.gov/37143846/Strength of Recommendation = B * Mastodon * * Tweet
2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia 2024 Focused Update: Guidelines on Use of Corticosteroids in... : Critical Care Medicine 2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia : Critical Care MedicineYou may evidence is available examining the use of corticosteroids in sepsis, acute respiratory distress syndrome (ARDS) and community-acquired pneumonia (CAP), warranting a focused update of the 2017 guideline on critical illness-related corticosteroid insufficiency.Objectives:To develop evidence-based recommendations for use of corticosteroids in hospitalized adults and children with sepsis, ARDS
Pneumonia vaccine is effective in people with inflammatory diseases Pneumonia vaccine effective in people with inflammatory diseasesPneumonia vaccine effective in people with inflammatory diseasesSkip to content * Accessibility options: * * Search articles Evidence * About us * Browse content * Brain and Nerves * Birth Conditions * Blood * Cancer * Dementia * Detection, Screening and Diagnosis sign up * Contact us * Homepage * > * Alert * > * Pneumonia vaccine is effective in people with inflammatory diseases Pneumonia vaccine is effective in people with inflammatory diseasesInflammatory and Immune System Disorders 17.12.24 doi: 10.3310/nihrevidence_65233 View commentaries and related content This is a plain English summary of an original research article. The views expressed are those